Catalyst Pharmaceuticals Inc [CPRX] stock is trading at $23.26, up 2.47%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CPRX shares have gain 0.87% over the last week, with a monthly amount glided 4.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] stock has seen the most recent analyst activity on February 04, 2025, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $28. Previously, Stephens started tracking the stock with Overweight rating on November 18, 2024, and set its price target to $35. On March 14, 2024, Citigroup initiated with a Buy rating and assigned a price target of $27 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $23 on March 07, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $30 as its price target on December 21, 2023. ROTH Capital downgraded its rating to Neutral for this stock on August 24, 2022, and upped its price target to $15.50. In a note dated September 21, 2018, Cantor Fitzgerald initiated an Overweight rating.
Catalyst Pharmaceuticals Inc [CPRX] stock has fluctuated between $13.12 and $24.64 over the past year. Currently, Wall Street analysts expect the stock to reach $31.5 within the next 12 months. Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] shares were valued at $23.26 at the most recent close of the market. An investor can expect a potential return of 35.43% based on the average CPRX price forecast.
Analyzing the CPRX fundamentals
Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] reported sales of 460.48M for the trailing twelve months, which represents a growth of 25.33%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.38%, Pretax Profit Margin comes in at 0.41%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.26 and Total Capital is 0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.77 points at the first support level, and at 22.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.51, and for the 2nd resistance point, it is at 23.75.
Ratios To Look Out For
For context, Catalyst Pharmaceuticals Inc’s Current Ratio is 5.11. In addition, the Quick Ratio stands at 4.92 and the Cash Ratio stands at 4.2. Considering the valuation of this stock, the price to sales ratio is 6.02, the price to book ratio is 4.20 and price to earnings (TTM) ratio is 19.84.
Transactions by insiders
Recent insider trading involved Miller Steve, Chief Op. & Scientific Officer, that happened on Dec 10 ’24 when 50000.0 shares were sold. Officer, Miller Steve completed a deal on Dec 10 ’24 to buy 50000.0 shares. Meanwhile, Chief Med. & Reg. Officer INGENITO GARY sold 12000.0 shares on Nov 27 ’24.
